Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 2, 2004, Pages 344-352

  Zhou, Hong ^a   Kim, Yeon Shil ^b   Peletier, Aaron ^a   McCall, Wes ^a   Earp, H Shelton ^a   Sartor, Carolyn I ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b The Catholic University of Korea   (South Korea)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; EGFR; GW572016; HER2; Radiosensitization; Radiotherapy; Tyrosine kinase inhibitors

Indexed keywords

CELLS; ENZYMES; RADIOTHERAPY; TUMORS;

RADIOSENSITIZATION;

ONCOLOGY;

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

BREAST CANCER; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOSENSITIVITY; RADIOSENSITIZATION; SIGNAL TRANSDUCTION;

EID: 0942268145     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.09.046     Document Type: Conference Paper

References (32)

1. Olayioye M.A., Neve R.M., Lane H.A., et al. The ErbB signaling network Receptor heterodimerization in development and cancer . EMBO J. 19:2000;3159-3167.
2. Riese D.J. II, Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays. 20:1998;41-48.
3. Yarden Y. The EGFR family and its ligands in human cancer Signaling mechanisms and therapeutic opportunities . Eur J Cancer. 37:(Suppl. 4):2001;S3-S8.
4. Arteaga C.L. The epidermal growth factor receptor From mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia . J Clin Oncol. 19:2001;32S-40S.
5. Ethier S.P., Lawrence T.S. Epidermal growth factor receptor signaling and response of cancer cells to ionizing radiation. J Natl Cancer Inst. 93:2001;890-891.
6. Sartor C. Epidermal growth factor family receptors and inhibitors: Radiation response modifiers. Semin Radiat Oncol 2003;13:22-30.
7. Harari P.M., Huang S.M. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol. 11:2001;281-289.
8. Ciardiello F., Tortora G. A novel approach in the treatment of cancer Targeting the epidermal growth factor receptor . Clin Cancer Res. 7:2001;2958-2970.
9. Baselga J. Targeting the epidermal growth factor receptor A clinical reality . J Clin Oncol. 19:2001;41S-44S.
10. Pietras R.J., Poen J.C., Gallardo D., et al. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59:1999;1347-1355.
11. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 1:2001;85-94.
12. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumor activity of GW572016 A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways . Oncogene. 21:2002;6255-6263.
13. Ignatoski K.M., Lapointe A.J., Radany E.H., et al. erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology. 140:1999;3615-3622.
14. Ethier S.P., Mahacek M.L., Gullick W.J., et al. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res. 53:1993;627-635.
15. Sartor C.I., Dziubinski M.L., Yu C.L., et al. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells. Cancer Res. 57:1997;978-987.
16. Sartor C.I., Zhou H., Kozlowska E., et al. HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 21:2001;4265-4275.
17. Bianco C., Tortora G., Bianco R., et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res. 8:2002;3250-3258.
18. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 59:1999;1935-1940.
19. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis . Clin Cancer Res. 6:2000;2166-2174.
20. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 51:2001;474-477.
21. Williams K, Telfer B, Stratford I, et al. Combination of ZD1839 (Iressa) and EGFR-TKI and radiotherapy increases antitumor efficacy in a human colon cancer xenograft. American Association for Cancer Research 92nd Annual Meeting. Vol. 42. New Orleans, LA: Cancer Research; 2001. p. A3480.
22. Solomon B., Hagekyriakou J., Trivett M.K., et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma Epidermal growth factor receptor . Int J Radiat Oncol Biol Phys. 55:2003;713-723.
23. Rao G.S., Murray S., Ethier S.P. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys. 48:2000;1519-1528.
24. Lawrence T.S., Nyati M.K. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Semin Radiat Oncol. 12:2002;33-36.
25. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol. 27:2000;46-52. discussion 92-100.
26. Albanell J., Codony-Servat J., Rojo F., et al. Activated extracellular signal-regulated kinases Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments . Cancer Res. 61:2001;6500-6510.
27. Baselga J. Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors Small molecules, big hopes . J Clin Oncol. 20:2002;2217-2219.
28. Moasser M.M., Basso A., Averbuch S.D., et al. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 61:2001;7184-7188.
29. Christensen J.G., Schreck R.E., Chan E., et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res. 7:2001;4230-4238.
30. Motoyama A.B., Hynes N.E., Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 62:2002;3151-3158.
31. Dent P., Yacoub A., Contessa J., et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res. 159:2003;283-300.
32. Kedar D., Baker C.H., Killion J.J., et al. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 8:2002;3592-3600.